The drug pricing reforms in the IRA have impacted, and may impact in the future, the prices of certain of our products.
All entries for: Dermatology
February 27, 2026
Aldeyra Therapeutics Inc
Neutral Outlook
Lexington, MA
1-50 employees
For that and other reasons, it is currently unclear how the IRA will be effectuated but it is likely to have a significant impact on the pharmaceutical industry.
Disease Area: Dermatology, Immune Diseases, Neurological Diseases, Oncology, Rare Diseases
Drug Type: Small Molecule
February 26, 2026
Kymera Therapeutics
Neutral Outlook
Watertown, MA
201-500 employees
The effect of IRA on our business and the pharmaceutical industry in general is not yet known.
Disease Area: Dermatology, Gastrointestinal, Immune Diseases, Oncology, Respiratory Diseases
Drug Type: Small Molecule
February 25, 2026
Arcus Biosciences, Inc.
Neutral Outlook
Hayward, CA
501-1,000 employees
For that and other reasons, it is currently unclear how the IRA will be effectuated, or the impact of the IRA on our business.
Disease Area: Dermatology, Immune Diseases, Oncology
Drug Type: Biologic, Small Molecule
February 25, 2026
Arcutis Biotherapeutics, Inc.
Neutral Outlook
Westlake Village, CA
201-500 employees
While the impact of the IRA on us and the pharmaceutical industry is likely to be significant, the impact on us cannot be fully determined.
Disease Area: Dermatology, Immune Diseases
Drug Type: Biologic, Small Molecule
February 24, 2026
AbCellera Biologics
Negative Outlook
British Columbia
501-1,000 employees
The implementation of cost-containment measures or other healthcare reforms may prevent us from generating revenue, achieving profitability, or commercializing our drug candidates if approved.
Disease Area: Dermatology, Endocrinology, Immune Diseases, Oncology
Drug Type: Biologic
February 17, 2026
Krystal Biotech
Neutral Outlook
Pittsburgh, PA
201-500 employees
It is unclear whether the Trump administration executive orders will lead to actual legislative initiatives. At this time, we continue to evaluate the effect of the IRA and the Trump administration’s executive actions on our business operations and financial condition and results as the full impact of the IRA and the executive actions remains uncertain.
Disease Area: Dermatology, Oncology, Other, Respiratory Diseases
Drug Type: Small Molecule
February 12, 2026
Vanda Pharmaceuticals
Neutral Outlook
Washington DC
201-500 employees
For these and other reasons, it is currently unclear how the IRA will be effectuated, and while the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.
Disease Area: Dermatology, Gastrointestinal, Multiple, Neurological Diseases, Psychiatry
Drug Type: Biologic, Small Molecule